TG Therapeutics: 3 Key Takeaways for Long-Term Investors

On its third-quarter 2026 earnings call, held on Nov. 9, 2026, TG Therapeutics (NASDAQ:TGTX) raised its full-year 2026 global revenue guidance to $1 billion. Commercial momentum for BRIUMVI, its intravenous (IV, meaning infused into a vein) antibody therapy targeting B cells for relapsing multiple sclerosis (MS, a chronic nervous system disease), is generating operating cash flow to fund pipeline expansion. Long-term investors are watching how management leverages this commercial base into new formulations and indications. Three things management said stand out.

1. Global Revenue Target Hits $1 Billion Annualized Run Rate

The company raised its full-year outlook as expanding prescriber adoption drove U.S. BRIUMVI revenue up 52% year over year. Higher sales volume provides operating leverage, turning top-line growth into cash flow that funds broader clinical development.

Looking ahead, we're raising our full-year revenue outlook to $915 million to $920 million in U.S. BRIUMVI net product revenue and approximately $1 billion in total global revenue, including projected payments from our ex-U.S. partner.
-- Sean Power, Chief Financial Officer

2. Subcutaneous Formulation Unlocks a Multibillion-Dollar Market Segment

Self-administered treatments account for roughly 35% of new anti-CD20 therapy starts. Adding a quarterly subcutaneous (subcu, injected under the skin) option allows TG Therapeutics to capture patients who prefer home administration without replacing its existing IV business.

We believe the addition of subcu can more than double BRIUMVI peak sales opportunity by opening an entirely new segment of the anti-CD20 market where we don't currently participate.
-- Adam Waldman, Chief Commercial Officer

3. Single-Dose IV Initiation Streamlines Patient Care

Management plans to simplify initiation by combining two separate starting infusions into a single session. Eliminating the second visit enhances convenience for patients and medical centers, which management expects will create demand tailwinds in the second half of 2027.

Based on physician feedback and our market research, we believe eliminating the second initiation infusion could become a meaningful driver of additional demand, providing further potential tailwinds to our IV business in the second half of '27 and beyond.
-- Adam Waldman, Chief Commercial Officer

Looking Ahead

Third-quarter U.S. net product revenue reached $233 million, and management is not hiding its satisfaction as expected fourth-quarter momentum pushes the annualized run rate above $1 billion. Expanding hospital adoption, high persistence, and a growing pool of treatment-naive patients reinforce commercial scale while clinical trials explore progressive MS.

Together, the opportunity to reach more patients, build on our existing commercial infrastructure and invest behind a long patent runway gives us confidence in BRIUMVI's substantial long-term growth potential.
-- Adam Waldman, Chief Commercial Officer

With patent protection extending into the mid-2040s and $557 million in cash and investments, TG Therapeutics retains financial flexibility to fund pipeline progress alongside share repurchases.

Our objective remains clear: to build a company capable of repeatedly creating value through scientific innovation, disciplined execution and thoughtful investments that generate attractive long-term returns.
-- Michael Weiss, Chairman and Chief Executive Officer

The Motley Fool recommends TG Therapeutics. The Motley Fool has a disclosure policy.